Micro-Computed Tomography를 사용한 소형 동물의 비침습적 골격근 정량화

Executive Industry Relevance

Non-invasive micro-CT quantification of skeletal muscle, adipose, and bone in small animals addresses a critical gap in preclinical metabolic and muscle disease research by enabling precise, longitudinal body composition analysis. Standardized imaging and segmentation protocols improve predictive confidence and translational continuity across studies, supporting robust target validation and mechanistic de-risking. This capability is essential for portfolio triage and risk-adjusted advancement in metabolic, geroscience, and muscle physiology pipelines.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables quantitative assessment of muscle and adipose tissue changes in response to interventions.
• Supports mechanistic de-risking by providing reproducible, high-resolution tissue composition data.
• Facilitates functional target validation through longitudinal monitoring within the same animal.

Screening & Assay Development

• Prepares validated animal models for downstream pharmacologic and metabolic screening workflows.
• Standardizes body composition measurement, enhancing assay reproducibility and comparability.
• Generates quantitative outputs for reliable compound evaluation and dose-response studies.

Translational & Preclinical Research

• Aligns preclinical models with disease-relevant endpoints such as age-related muscle loss and fat accumulation.
• Enables continuity from early discovery through preclinical validation by supporting repeated, non-destructive measurements.
• Improves risk-adjusted advancement decisions by providing robust, quantitative biomarkers of tissue change.

Pipeline & Workflow Integration

Micro-CT body composition analysis integrates from early discovery through lead identification and preclinical validation, supporting hypothesis testing and translational biomarker development.

• Discovery Biology: Provides quantitative, non-invasive readouts for hypothesis-driven studies of muscle and metabolic function.
• Screening: Delivers standardized, reproducible tissue segmentation and volume measurements for assay readiness.
• Analytics: Outputs precise volumetric and mass data, enabling statistical comparison across experimental groups and time points.
• Translational Research: Supports alignment with clinical endpoints by modeling age-related and disease-relevant body composition changes.
• Enterprise Reuse: Establishes a reusable imaging and analysis platform for diverse metabolic, muscle, and aging studies.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in preclinical models.
• Operational Value: Enhances standardization, reproducibility, and scalability of body composition analysis.
• Strategic Value: Enables better go/no-go decisions and capital efficiency by providing robust, quantitative endpoints.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of metabolic and muscle disease programs.

Implementation Considerations

• Requires expertise in micro-CT imaging, segmentation, and quantitative analysis.
• Needs access to high-resolution preclinical imaging systems and compatible analysis software.
• Demands protocol standardization and cross-team training for consistent data acquisition and interpretation.
• Must adapt segmentation thresholds and analysis parameters for different animal models and tissue types.
• Potential limitations include anatomical variability and the need for careful calibration of Hounsfield units.

Biopharma FAQs